Abstract
Osteogenesis Imperfecta (OI), popularly known as brittle bone disease, is characterized by bone fragility and deformities, as well as fractures caused by minor trauma. Prevention to reduce the number of fractures, treatment of fractures and surgical correction of deformities are a challenge for orthopaedic surgeons in their therapeutic management. The aim of this study is to analyze the therapeutic approaches to osteogenesis imperfecta in Brazil from 2013 to 2022. This is a retrospective qualitative and quantitative clinical investigation, in which the information was obtained from the Ministry of Health databases (TABNET), made available by the Department of Informatics of the Unified Health System (DATASUS), using the health science descriptors: "osteogenesis imperfecta", "pediatrics" and "bone fractures". It can be seen that between 2013 and 2022, 9,461 treatments for osteogenesis imperfecta were recorded in Brazil, so even though it is considered a rare pathology, it has a significant number of cases. Thus, the long-term aim of therapeutic interventions is for these children to live independently and develop the life skills that will enable them to coordinate their own care
Reference57 articles.
1. Augarten A, Laufer J, Szeinberg A, et al. Child abuse, osteogenesis imperfecta and the grey zone between them. J Med. 1993;24(2-3):171-175.
2. child abuse;EV. Osteogenesis imperfecta vs;Am J Med Genet,1994
3. Type I osteogenesis imperfecta: a nonfunctional allele for pro alpha 1 (I) chains of type I procollagen;Barsh;Proc Natl Acad Sci U S A,1982
4. Bateman JF, Moeller I, Hannagan M, et al. Characterization of three osteogenesis imperfecta collagen alpha 1(I) glycine to serine mutations demonstrating a position-dependent gradient of phenotypic severity. Biochem J. 1992;288 ( Pt 1)(Pt 1):131-135.
5. Assis MC, Plotkin H, Glorieux FH, et al. Osteogenesis imperfecta: novos conceitos. Rev Bras Ortop. 2002;37(8).